London-based uMotif, a software that captures patient data for clinical studies, has raised £5 million in a Series A round led by existing investor AlbionVC, with participation from Norwegian firm DNV GL and angel investors. By creating a more engaging experience for study participants, uMotif aims to capture larger volumes of higher quality data. Pharmaceutical and biotech companies use the cloud-based platform to capture such clinical research data, configuring the software to each study’s needs. The benefits include not just more and better data, but different data. The mobile and user-friendly nature of the app means clinical studies could reach new patient populations, increasing diversity in medical research. And the result is to “ultimately help our customers to get new therapies to patients faster,” says CEO and co-founder Bruce Hellman. So far the UK startup is involved with studies in 26 countries, from clinical to “real-world” outpatient settings, and across more than 25 therapeutic areas, from dermatology and rare disease to oncology and cardiology. The fresh capital will drive all sorts of expansion — developing the product for new study types and high-demand territories, and driving commercial growth across Europe and the US.
Photo: the uMotif team